tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Weekly

tanzania times : Latest News and In-depth Analysis
HomeWeekly
Weekly

Mar 18, 2025

Vantage Recognized with 'Best Global Broker' Award at Money Expo Mexico 2025

PORT VILA,Vanuatu,March 17,2025-- Vantage Markets participated as a Titanium Sponsor at Money Expo Mexico 2025,held on February 26-27. The event,known as one of the most significant gatherings for tr

All News

NETSCOUT Applauded by Frost & Sullivan for Enabling Real-Time Visibility into Network Traffic with Competitive Strategies

NETSCOUT\'s solutions provide actionable intelligence through powerful deep packet inspection,behavioral analytics,and AI-driven insights

Feb 26, 2025

Weekly

LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region

PORT MELBOURNE,Australia and JOHNSON CITY,Tenn.,Feb. 24,2025-- LabConnect and Australian Clinical Labs\' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical tr

Feb 26, 2025

Weekly

Driving Impact: Southeast Asia as a Rising Force in Social Developments and Impact Investing

The region\'s rising maturity and rapid economic growth position it as a critical player in addressing social issues,

Feb 26, 2025

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

HONG KONG,Feb. 25,2025--Akeso,Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab,Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a c

Feb 26, 2025

CNPC's Well Shendi Take-1 reaches 10,910-meter milestone

BEIJING,Feb. 25,2025-- A news report from chinadaily.com.cn: On February 20,China National Petroleum Corporation (CNPC) announced the successful completion of the Well Shendi Take-1,reaching an impres

Feb 26, 2025

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

SHANGHAI,Feb. 25,2025-- YolTech Therapeutics,a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines,today reported positive results fr

Feb 26, 2025

1 ... 52 53 54 55 56 57 58 ... 108